Patents Assigned to Inserm
  • System for stimulation therapy of the vagus nerve by implementation of a self-adaptive state transition model based on physical or physiological levels
    Patent number: 10124173
    Abstract: One system includes a stimulation device such as a vagus nerve stimulation lead, and a controller for controlling the stimulation device according to a set of stimulation parameters. A memory of the stimulation device contains a state transition model, and for each state defines a set of stimulation parameters and at least one expected response during the application of stimulation with the parameters. A matrix determines the transition rules between states based on physiological levels measured versus target levels. A state transition control unit determines, in an organized timely method, possible transitions between states according to the rules on physiological levels obtained in response to the implementation of the stimulation parameters of the current state, and a transition from a current state to a new state causes a corresponding change in the parameter set used for stimulation.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: November 13, 2018
    Assignees: SORIN CRM SAS, UNIVERSITE DE RENNES 1, INSERM- INSTITUT DE LA RECHERCHE MEDICALE
    Inventors: Jean-Luc Bonnet, Alfredo Hernandez, Guy Carrault, Hector Romero, Virginie Le Rolle
  • Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof
    Patent number: 10123976
    Abstract: The present invention relates to a method for preparing poloxamer-protein particles. It also relates to poloxamer-protein particles obtainable by this method, dispersion thereof, and their use in methods of encapsulation, in particular of microencapsulation.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: November 13, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ETDE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE D'ANGERS
    Inventors: Alexandra Paillard, Marie-Claire Venier, Jean-Pierre Benoit
  • N1-And N7-Substituted Sibiriline Derivatives And Their Use As Inhibitor Of Cellular Necroptosis
    Publication number: 20180312502
    Abstract: The present invention relates to new N1- and N7-substituted sibiriline derivatives of the following general formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as drug, in particular for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising such a compound and processes to prepare such a compound. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
    Type: Application
    Filed: October 13, 2016
    Publication date: November 1, 2018
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Universite Claude Bernard Lyon 1
    Inventors: Marie-Thérèse Dimanche-Boitrel, Stéphane Bach, Claire Delehouze, Peter Goekjian, Arnaud Comte
  • ENDONUCLEASE-BARCODING
    Publication number: 20180312831
    Abstract: The instant invention relates to a method for labeling endonuclease-treated cells, comprising the steps of: a) providing cells or a composition comprising cells; b) bringing into contact said cells or said composition with: —at least one endonuclease suitable for targeting a genomic region of interest in said cells, or a vector suitable for expressing said endonuclease in said cells; —at least one first nucleic acid suitable for introducing one or more silent mutation(s) in said genomic region by homology-directed repair (HDR), and optionally one or more non-silent mutation(s); and —at least one second nucleic acid suitable for introducing one or more silent mutation(s) in said genomic region by homology-directed repair (HDR), but distinct from the silent mutations of the first nucleic acid; thereby labeling endonuclease-treated cells.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 1, 2018
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Rouen Normandie
    Inventor: Luca Grumolato
  • METHOD FOR REJUVENATING CELLS
    Publication number: 20180312813
    Abstract: The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stein cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population tinder appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, Myc, Lin28 and, optionally Nanog.
    Type: Application
    Filed: July 6, 2018
    Publication date: November 1, 2018
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE MONTPELLIER I, UNIVERSITE MONTPELLIER II
    Inventors: Alexandre Prieur, Ollivier Milhavet, Jean-Marc Lemaitre, Laure Lapasset
  • Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse
    Patent number: 10111896
    Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 30, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Universite Paris Descartes, Foundation Imagine, Universite Paris Diderot—Paris 7, Universite Paris—Sud, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Etienne Paubelle, Michael Dussiot, Thiago Trovati Maciel, Florence Zylbersztejn
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES
    Publication number: 20180305458
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory disease. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R agonist.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS DIDEROT - PARIS 7, UNIVERSITÉ DE ROUEN NORMANDIE
    Inventors: Yossan-Var TAN, Catalina ABAD-RABAT, Alain COUVINEAU, Thierry VOISIN
  • Phosphorylated dendrimers as antiinflammatory drugs
    Patent number: 10106565
    Abstract: Dendrimers with monophosphonic or bisphosphonic terminations for the treatment of inflammatory diseases.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: October 23, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER (TOULOUSE III)
    Inventors: Mary Poupot, Remy Poupot, Jean-Jacques Fournie, Damien Portevin, Severine Fruchon, Jean-Luc Davignon, Cedric-Olivier Turrin, Anne-Marie Caminade, Jean-Pierre Majoral, Olivier Rolland
  • FLT3 receptor antagonists for the treatment or the prevention of pain disorders
    Patent number: 10106798
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: October 23, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
    Inventor: Jean Valmier
  • Isolated donor MHC-derived peptide and uses thereof
    Patent number: 10105425
    Abstract: The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to an isolated peptide of 15 or 16 amino acids long that comprises or consists of the amino acid sequence: REEYARFDSDVGEYR (SEQ ID NO: 1) or a function-conservative variant for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8+CD45RClow Tregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8+CD45RClow Tregs is indicative of tolerance.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: October 23, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes
    Inventors: Carole Guillonneau, Ignacio Anegon, Elodie Picarda
  • Auto-inducible expression system
    Patent number: 10106801
    Abstract: A method for the expression of a protein of interest by a bacterium, notable in that it comprises the culturing of a bacterium temporarily or continuously expressing an Hsp protein, in that said bacterium also comprises a nucleic acid sequence, encoding a protein of interest, under the control of a lac promoter and in that said bacterium is cultured in a medium which does not contain IPTG or a metabolized molecule in such a way as to automatically induce the induction of transcription from the lac promoter.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: October 23, 2018
    Assignees: UNIVERSITE DE BOURGOGNE, INRA, INSERM
    Inventors: Fabrice Neiers, Renaud Seigneuric, Loïc Briand, Carmen Garrido-Fleury
  • Nucleic acids targeting TCTP for use in the treatment of chemo- or hormone-resistant cancers
    Patent number: 10105384
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: October 23, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II
    Inventors: Palma Rocchi, Virginie Baylot, Julie Acunzo, Claudia Andrieu, Maria Katsogiannou
  • Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject
    Patent number: 10105452
    Abstract: The present invention relates to methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject. In particular, the present invention relates to a method for selectively expressing a polynucleotide of interest in the retinal pigment epithelium in an eye of a subject in need thereof comprising the step of transducing the retinal pigment epithelium with an amount of a rAAV2/5 vector containing the polynucleotide of interest.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: October 23, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Christian Hamel, Vasiliki Kalatzis, Marie Pequignot, Nicolas Cereso
  • Methods For Detecting Or Quantifying CTP And CTP Synthase Activity
    Publication number: 20180298420
    Abstract: The present invention relates to a method for detecting or quantifying CTP in a cell sample comprising at least two nucleotide triphosphates by cationic ion pairing chromatography coupled to mass spectrometry, to a method for detecting or quantifying CTP synthase activity based on the method for detecting or quantifying CTP, and to their use in methods for screening potential immunosuppressive or anti-cancer compounds and in methods for determining the appropriate dose of an immunosuppressive or anti-cancer compound inhibiting CTP synthase activity for a treated subject.
    Type: Application
    Filed: October 10, 2016
    Publication date: October 18, 2018
    Applicants: Assistance Publique-Hopitaux de Paris, Imagine Institut Des Maladies Genetiques Necker Enfants Malades, Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Sylvia Sanquer, Anne-Claire Boschat, Sylvain Latour, Emmanuel Martin, Robert Barouki
  • Use of Mcoln-1 modulators to regulate cell migration
    Patent number: 10100313
    Abstract: The present invention relates to the use of modulators of Mcoln-1 for modulating cell migration, in particular the migration of dendritic cells and tumor cells, especially for antitumoral vaccination, autoimmune disease treatment, and metastasis prevention.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: October 16, 2018
    Assignees: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Ana-Maria Lennon-Dumenil, Pablo Vargas, Marine Bretou
  • Methods and pharmaceutical compositions for the treatment of ebola virus disease
    Patent number: 10098879
    Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of Ebola Virus Disease. In particular the present relates to a method of treating Ebola Virus Disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of Favipiravir.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: October 16, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BORDEAUX, CHU DE BORDEAUX, TOYAMA CHEMICAL CO., LTD
    Inventors: Denis Malvy, Sylvain Baize, Xavier De Lamballerie, Hervé Raoul, Cédric Laouenan, Jeremie Guedj, France Mentre
  • Adjustable speed fast laser scanning system and two-photon microscope associated
    Patent number: 10101634
    Abstract: The present invention concerns a laser scanning system (18) comprising: —a first acousto-optical deflector (30) deflecting a beam in a first direction (X) to obtain a first deflected beam and comprising a first acousto-optical crystal on which is applied an acoustic wave whose frequency varies over time according to a first law of command, and —a second acousto-optical deflector (32) deflected the first deflected beam in a second direction (Y), defining an angle comprised between 85° and 95° with the first direction, and comprising a second acousto-optical crystal on which is applied an acoustic wave whose frequency varies over time according to a second law of command, characterized in that the first law of command and the second law of command are chosen so that the average speed of the laser scanning system (18) is superior to 10 radians per second.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 16, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Ecole Normale Superieure
    Inventors: Stéphane Dieudonne, Benjamin Mathieu
  • Use of a reverse-transcriptase inhibitor in the prevention and treatment of degenerative diseases
    Patent number: 10100307
    Abstract: The invention relates to the use of a reverse-transcriptase inhibitor in the prevention or treatment of a degenerative disease.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: October 16, 2018
    Assignees: Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale (INSERM), College de France, Sorbonne Universite
    Inventors: Alain Prochiantz, Julia Fuchs, Rajiv Joshi, François Xavier Blaudin De The, Hocine Rekaik, Olivia Massiani-Beaudoin
  • Tetrahydroquinoline derivatives and their use as Epac inhibitors
    Patent number: 10093627
    Abstract: The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: October 9, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER TOULOUSE III, UNIVERSITE PARIS-SUD, UNIVERSITE D'ORLEANS
    Inventors: Frank Lezoualc'h, Rodolphe Fischmeister, Malik Bisserier, Pascal Bouyssou, Jean-Paul Blondeau, Delphine Courilleau
  • RECEPTOR-BINDING DOMAINS LIGANDS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER
    Publication number: 20180280549
    Abstract: Disclosed are methods for diagnosing pancreatic cancer, including measuring the expression level of ASCT1 and/or ASCT2 and/or XPR1. Also disclosed is a RBD ligand coupled to at least one contrast agent, that may be used as a probe for medical imaging.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 4, 2018
    Applicants: METAFORA BIOSYSTEMS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Jawida TOUHAMI, Guangqi E, Donatella GIOVANNINI, Bruno ROBERT, Samuel SEVESTRE, Muriel BUSSON, Jean-Luc BATTINI, Vincent PETIT, Marc SITBON